cfDNA Methylation Assay for Clinical Evaluation of Patients With Stage IA Lung Cancer After Ablation Operation
Lung Cancer
About this trial
This is an interventional treatment trial for Lung Cancer focused on measuring ablation, circulating free DNA, methylation
Eligibility Criteria
Inclusion Criteria:
- Age: 18-85 years old;
- The peripheral pulmonary nodules found in patients with chest CT, preoperative examination showed that the clinical stage of patients was T1N0M0, IA;
- patients are not suitable for surgical treatment through multidisciplinary assessment, agree to accept ablation
- Patients have good compliance with the tests and follow-ups, understand the situation of the study and sign informed consent.
Exclusion Criteria:
- The patient is generally in poor condition and cannot tolerate the examination;
- patients with a cardiac pacemaker or stent in the heart; peripheral tumors of the lungs are adjacent to large blood vessels or important structures;
- patients with poor compliance;
- Researchers believe that it is not appropriate to participate in this trial.
Sites / Locations
- Shanghai Chest HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
ablation group
surgery group
Patients with stage IA inoperable peripheral lung tumor will be performed ablation. cfDNA methylation would be monitored at different times(before surgery , after surgery 1month, 3month, and every 3month in the first year and every 6 months in the second ). Meanwhile, post-treatment response will be evaluated and follow up will be carried out according to the standard procedure.
Patients with stage IA operable peripheral lung tumor will be performed surgery. cfDNA methylation would be monitored at different time(before surgery , after surgery 1month, 3month). Post-treatment response will be evaluated and follow up will be carried out according to the standard procedure.